NF-1C Inhibitors
NF-1C inhibitors constitute a diverse group of compounds that exert their effects through specific interactions with various signaling pathways intersecting with NF-1C-regulated cascades. A prominent member of this class is Aloxistatin (CAS: 178305-76-7), a selective matrix metalloproteinase (MMP) inhibitor. Aloxistatin modulates extracellular matrix (ECM) remodeling, indirectly influencing NF-1C by altering cell-matrix interactions and downstream signaling pathways intricately linked to NF-1C regulation. The dynamic nature of the extracellular environment plays a crucial role in shaping cellular responses, and Aloxistatin's impact on MMPs highlights its potential in modulating NF-1C through alterations in the cellular microenvironment. Another noteworthy NF-1C inhibitor is Wortmannin (CAS: 19545-26-7), which targets phosphoinositide 3-kinase (PI3K), disrupting the PI3K/Akt pathway. This disruption indirectly impacts NF-1C by interrupting Akt-mediated signaling cascades that intersect with NF-1C-regulated pathways. The intricate cross-talk between PI3K/Akt and NF-1C signaling underscores the interconnectedness of these pathways and the potential of Wortmannin to modulate NF-1C activity through strategic targeting of shared downstream effectors.
Bay 11-7082 (CAS: 19542-67-7) is another inhibitor within this class that inhibits IκBα phosphorylation, suppressing the NF-κB pathway. By doing so, it influences NF-1C through disruption of downstream effector pathways shared between NF-κB and NF-1C. This compound exemplifies how inhibitors can strategically impact multiple pathways, leading to nuanced effects on the cellular processes regulated by NF-1C. Rapamycin (CAS: 53123-88-9) and LY294002 (CAS: 154447-36-6) target mTOR and PI3K, respectively, altering the shared downstream effectors between their respective pathways and NF-1C. These compounds showcase the intricate crosstalk between signaling pathways, forming the basis of NF-1C inhibition. By influencing key nodes within these interconnected networks, Rapamycin and LY294002 provide additional layers of modulation to NF-1C activity, emphasizing the complexity of cellular regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences NF-1C by targeting the PI3K pathway. Inhibiting PI3K disrupts downstream signaling events that intersect with NF-1C function. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, indirectly modulates NF-1C by affecting Raf kinase and downstream signaling pathways. By interfering with Raf, Sorafenib alters NF-1C activity through cross-talk mechanisms. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly influences NF-1C by disrupting the PI3K pathway. Inhibiting PI3K alters downstream signaling events, impacting NF-1C activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, indirectly modulates NF-1C by interfering with the MAPK pathway. Inhibiting MEK disrupts the phosphorylation cascade, influencing NF-1C activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly influences NF-1C by targeting the NF-κB signaling pathway. Inhibiting NF-κB alters downstream events affecting NF-1C activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly modulates NF-1C by affecting the mTOR pathway. Inhibiting mTOR disrupts downstream signaling events influencing NF-1C activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly influences NF-1C by targeting the p38 MAPK pathway. Inhibiting p38 MAPK disrupts the downstream events that intersect with NF-1C function. dysregulation of these pathways contributes to pathogenesis. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly modulates NF-1C by affecting the TGF-β signaling pathway. Inhibiting TGF-β receptor disrupts downstream events influencing NF-1C activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly influences NF-1C by targeting the JNK signaling pathway. Inhibiting JNK disrupts downstream events that intersect with NF-1C function. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490, a JAK2 inhibitor, indirectly modulates NF-1C by targeting the JAK-STAT pathway. Inhibiting JAK2 disrupts downstream events influencing NF-1C activity. | ||||||